Bend, OR – Bend Research Inc., a leading independent drug-formulation development and manufacturing company, announced the expansion of its existing hot-melt extrusion (HME) capacity with the addition of an 18mm Leistritz twin-screw mixer/extruder.
The 18mm Leistritz twin-screw mixer/extruder complements Bend Research's existing 27mm Leistritz and 19mm Baker Perkins extruder units, enhancing the company's melt-extrusion and continuous high-shear wet-granulation capabilities. Many projects have been successfully advanced through the use of extrusion, including one product brought to market with Bend Research's HME technology.
The 18mm extruder will blend seamlessly into Bend Research's science and engineering-based work flows for amorphous dispersions. Additionally, it will complement the company's core offerings in oral solubilization, including spray-dried dispersions (SDDs) and crystal size reduction.
"As a leader in solubility enhancement and an expert in hot-melt extrusion, we work hard to continually improve and expand in ways that minimize the time, money, and active pharmaceutical ingredient required to advance these projects," explained Rod Ray, chairman and chief executive officer at Bend Research. "The addition of this equipment enables us to use less API during formulation and process development, as well as allows for more facile transfer and scale-up from development through clinical trial manufacturing in our cGMP manufacturing facility."
For a complete listing of Bend Research's development and manufacturing equipment, please visit: http://www.bendresearch.com/content/cgmp-manufacturing.
About Bend Research Inc.
For more than 35 years, Bend Research has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding.
Bend Research provides several capabilities, including formulation and dosage-form support, assists in process development and optimization, manufactures clinical-trial quantities of drug candidates in its cGMP facilities, and advances promising drug candidates from conception through commercialization. Bend Research is a leader in novel formulations, including SDDs and hot-melt extrusions, and controlled-release, inhalation, and biotherapeutics technologies.
Bend Research has more than 275 employees based in four state-of-the-art facilities in Bend, Ore., USA.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.